Skip to content

Real time vs. Flash glucose monitoring in type 1 diabetes - a cross-over trial

Real time vs. Flash glucose monitoring in type 1 diabetes - a cross-over trial - RT-CGM vs. FGM in T1D

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON51332
Enrollment
48
Registered
2023-03-08
Start date
2022-10-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus

Interventions

None listed

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Type 1 diabetes mellitus (as defined by the American Diabetes Association criteria) for >= 6 months - Intensive insulin regimen consisting of MDI (basal-bolus with > 3 injections/day) or CSII established for more than 3 months - Blood glucose control for >= 4 times per day, either using fingerprick measurements, FSL-FGM or rt-CGM established for more than 3 months - Age 18 to 75 years - HbA1c

Exclusion criteria

Exclusion criteria: - Oral of injected steroid using within the past 3 months - Pregnancy or planned pregnancy - Uncontrolled thyroid disease or uncontrolled hypertension - Poor visual acuity - Inability or unwillingness to meet the protocol requirements - Severe cognitive impairment - Any severe or uncontrolled medical or psychological condition which, in the opinion of the investigator, would compromise the ability to meet protocol requirements.

Design outcomes

Primary

MeasureTime frame
Primary endpoint is the difference in percentage of time in the hypoglycemic (defined as glucose

Secondary

MeasureTime frame
Secondary outcomes include changes in glucose control, sensor performance, changes in clinical parameters, PROs and PREs (including health related quality of life, treatment satisfaction, fear of hypoglycemia, diabetes distress and patient preference) during and between both treatment phases.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)